

Drug Monograph

Drug/Drug Class: **Invokamet XR[®] (canagliflozin and metformin hydrochloride) extended release tablet/ Diabetic Combination Products**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Invokamet XR[®] is available as an extended-release, film-coated tablet in strengths of 50 mg canagliflozin/ 500 mg metformin, 50 mg canagliflozin/ 1,000 mg metformin, 150 mg canagliflozin/ 500 mg metformin, and 150 mg canagliflozin/ 1,000 mg metformin respectively.

Manufacturer: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560

Indications: Invokamet XR[®] is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.

Costs: \$6.52 per tablet of each strength of Invokamet XR[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications No PA Required

Prepared By: Luke Boehmer Pharm.D.

Date: November 29, 2016